Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE—To assess the efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes and inadequate glycemic control on diet and exercise. RESEARCH DESIGN AND METHODS—In a 24-week, randomized, double-blind, placebo-controlled, parallel-group study, 1,091 patients with type 2 diabetes and A1C 7.5–11% were randomized to one of six daily treatments: sitagliptin 100 mg/metformin 1,000 mg (S100/M1000 group), sitagliptin 100 mg/metformin 2,000 mg (S100/M2000 group), metformin 1,000 mg (M1000 group), metformin 2,000 mg (M2000 group) (all as divided doses administered twice daily [b.i.d.]), sitagliptin 100 mg q.d. (S100 group), or placebo. Patients who had an A1C >11% or a fasting glucose value >280 mg/dl after the run-in period were not eligible to be randomized; these patients could participate in an open-label substudy and were treated with S100/M2000 for 24 weeks. RESULTS—The mean baseline A1C was 8.8% in the randomized patients. The placebo-subtracted A1C change from baseline was −2.07% (S100/M2000), −1.57% (S100/M1000), −1.30% (M2000), −0.99% (M1000), and −0.83% (S100) (P < 0.001 for comparisons versus placebo and for coadministration versus respective monotherapies). The proportion of patients achieving an A1C <7% and <6.5% was 66 and 44%, respectively, in the S100/M2000 group (P < 0.001 vs. S100 or M2000). For the open-label cohort (n = 117; baseline A1C 11.2%) treated with S100/M2000, the within-group mean A1C change from baseline was −2.9%. The incidence of hypoglycemia was low (0.5–2.2%) across active treatment groups and not significantly different from that in the placebo group (0.6%). The incidence of gastrointestinal adverse experiences was similar for coadministration therapies compared with their respective metformin monotherapy. CONCLUSIONS—The initial combination of sitagliptin and metformin provided substantial and additive glycemic improvement and was generally well tolerated in patients with type 2 diabetes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DPP-4 inhibitors lower A1C levels by 0.6-0.9 percentage points and are weight neutral and relatively well tolerated.
“In clinical trials performed to date, DPP-4 inhibitors lower A1Clevels by 0.6–0.9 percentage points and are weight neutral and relatively well tolerated (83,84).”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,831 · see citing works
Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357 · see citing works
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342 · see citing works
Oral Antihyperglycemic Therapy for Type 2 Diabetes
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,057 · see citing works
Aschner, P. J., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams‐Herman, D., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 878 · see citing works
Self-citationKim, D., Wang, L., Beconi, M. G., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K. A., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 827 · see citing works
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790 · see citing works
Self-citationThe Importance of -Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7713 · Cited by 694 · see citing works
Nauck, M. A., Meininger, G. E., Sheng, D., Terranella, L., Stein, P. P., & Sitagliptin Study 024 Group (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00704.x · Cited by 656 · see citing works
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614 · see citing works
Self-citationRosenstock, J., Brazg, R., Andryuk, P. J., Lu, K., & Stein, P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.007 · Cited by 514 · see citing works
Herman, G. A., Bergman, A. J., Stevens, C., Kotey, P. N.-A., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrödter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495 · see citing works
EINHORN, D. F., Rendell, M., Rosenzweig, J. L., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)83039-8 · Cited by 367 · see citing works
Hundal, R. S., & Inzucchi, S. E. (2003) · Drugs · doi:10.2165/00003495-200363180-00001 · Cited by 312 · see citing works
The evolution of β‐cell dysfunction and insulin resistance in type 2 diabetes
Bergman, R. N., Finegood, D. T., & Kahn, S. E. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.5.x · Cited by 302 · see citing works
Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300 · see citing works
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255 · see citing works
Evaluation of risk factors for development of complications in Type II diabetes in Europe
Liebl, A., Mata, M., & Eschwége, E. (2002) · Diabetologia · doi:10.1007/s00125-002-0863-0 · Cited by 250 · see citing works
Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy
Bloomgarden, Z. T., Dodis, R., Viscoli, C. M., Holmboe, E. S., & Inzucchi, S. E. (2006) · Diabetes Care · doi:10.2337/dc06-1120 · Cited by 219 · see citing works
Setter, S. M., Iltz, J. L., Thams, J., & Campbell, R. K. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90089-0 · Cited by 192 · see citing works
Garber, A. J., Larsen, J. L., Schneider, S. H., Piper, B. A., Henry, D. A., & The Glyburide/Metformin Initial Therapy Study Group (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00211.x · Cited by 138 · see citing works
Efficacy of Glyburide/Metformin Tablets Compared with Initial Monotherapy in Type 2 Diabetes
Garber, A. J., Donovan, D. S., Dandona, P., BRUCE, S. R., & Park, J.-S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021225 · Cited by 116 · see citing works
Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1
Hinke, S. A., Kühn‐Wache, K., Hoffmann, T., Pederson, R. A., McIntosh, C. H. S., & Demuth, H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6607 · Cited by 105 · see citing works
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments
Lenhard, J. M., Croom, D. K., & Minnick, D. T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.021 · Cited by 90 · see citing works
Rosenstock, J., Rood, J. A., Cobitz, A. R., Biswas, N., Chou, H. S., & Garber, A. J. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00659.x · Cited by 87 · see citing works
Tura, A., Pacini, G., Kautzky‐Willer, A., Ludvik, B. H., Prager, R., & Thomaseth, K. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00104.2002 · Cited by 42 · see citing works
Deeks, E. D., & Scott, L. J. (2006) · Drugs · doi:10.2165/00003495-200666140-00007 · Cited by 20 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · see citing works
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,345 · see citing works
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893 · see citing works
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · see citing works
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712 · see citing works
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 645 · see citing works
Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 582 · see citing works
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435 · see citing works
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 435 · see citing works
Kennedy, L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79145-5 · Cited by 425 · see citing works
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
Åhrén, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2782 · Cited by 417 · see citing works
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., & Shekelle, P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 399 · see citing works
Kim, Y. G., Hahn, S., Oh, T. J., Kwak, S. H., Park, K. S., & Cho, Y. (2013) · Diabetologia · doi:10.1007/s00125-012-2827-3 · Cited by 396 · see citing works
Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V. (2014) · Diabetes Care · doi:10.2337/dc13-2759 · Cited by 341 · see citing works
Russell-Jones, D. L., Cuddihy, R. M., Hanefeld, M., Kumar, A., González‐González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2011) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 334 · see citing works
Metformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318 · see citing works
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul‐Ghani, M. A. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 316 · see citing works
Henry, R. R., Murray, A. V., Marmolejo, M. H., Hennicken, D., Ptaszynska, A., & List, J. F. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02911.x · Cited by 312 · see citing works
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006739.pub2 · Cited by 308 · see citing works
A review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 307 · see citing works
Jadzinsky, M. N., Pfützner, A., Paz-Pacheco, E. T., Xu, Z., Allen, E., Chen, R., & CV181‐039 Investigators (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01056.x · Cited by 294 · see citing works
Raz, I., Chen, Y., Wu, M., Hussain, S., Kaufman, K. D., Amatruda, J. M., Langdon, R. B., Stein, P. P., & Alba, M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260925 · Cited by 261 · see citing works
Williams‐Herman, D., Engel, S. S., Round, E., Johnson, J. R., Golm, G. T., Guo, H., Musser, B. J., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-7 · Cited by 257 · see citing works
Self-citationNathan, D. M., Buse, J. B., Kahn, S. E., Krause-Steinrauf, H. J., Larkin, M., Staten, M. A., Wexler, D. J., & Lachin, J. M. (2013) · Diabetes Care · doi:10.2337/dc13-0356 · Cited by 255 · see citing works
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Aroda, V. R., Henry, R. R., Han, J., Huang, W., DeYoung, M. B., Darsow, T., & Hoogwerf, B. J. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.013 · Cited by 253 · see citing works
Li, L., Li, S., Deng, K., Liu, J., Vandvik, P. O., Zhao, P., Zhang, L., Shen, J., Bała, M. M., Sohani, Z. N., et al. (2016) · BMJ · doi:10.1136/bmj.i610 · Cited by 237 · see citing works
Dicker, D. (2011) · Diabetes Care · doi:10.2337/dc11-s229 · Cited by 227 · see citing works
Incretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 221 · see citing works
Scott, R. S., Loeys, T., Davies, M. J., Engel, S. S., & for the Sitagliptin Study 801 Group (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00839.x · Cited by 218 · see citing works
Self-citationComparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas
Deacon, C. F., & Lebovitz, H. E. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12610 · Cited by 217 · see citing works
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
Baetta, R., & Corsini, A. (2011) · Drugs · doi:10.2165/11591400-000000000-00000 · Cited by 211 · see citing works
Qaseem, A., Barry, M. J., Humphrey, L. L., & Forciea, M. A. (2017) · Annals of Internal Medicine · doi:10.7326/m16-1860 · Cited by 206 · see citing works
Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control
Hirst, J. A., Farmer, A. A., Ali, R., Roberts, N. W., & Stevens, R. (2012) · Diabetes Care · doi:10.2337/dc11-1465 · Cited by 204 · see citing works
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
Nonaka, K., Kakikawa, T., Sato, A., Okuyama, K., Fujimoto, G., Kato, N., Suzuki, H., Hirayama, Y., Ahmed, T., Davies, M. J., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.08.021 · Cited by 203 · see citing works
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
Scheen, A. J. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.001 · Cited by 198 · see citing works
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 189 · see citing works
Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 177 · see citing works
Migoya, E. M., Bergeron, R., Miller, J., Snyder, R., Tanen, M., Hilliard, D., Weiss, B., Larson, P., Gutierrez, M., Jiang, G., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.184 · Cited by 177 · see citing works
Self-citationDipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
Monami, M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.015 · Cited by 173 · see citing works
Bosi, E., Dotta, F., Jia, Y., & Goodman, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01040.x · Cited by 173 · see citing works
Arechavaleta, R., Seck, T. L., Chen, Y., Krobot, K. J., O’Neill, E. A., DURAN, L., Kaufman, K. D., Williams‐Herman, D., & Goldstein, B. J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01334.x · Cited by 170 · see citing works
Self-citationScheen, A. J., Charpentier, G., Östgren, C. J., Hellqvist, Å., & Gause‐Nilsson, I. A. M. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1114 · Cited by 167 · see citing works
Umpierrez, G. E., Gianchandani, R., Smiley, D., Jacobs, S., Wesorick, D. H., Newton, C., Farrokhi, F., Peng, L., Reyes, D., Lathkar-Pradhan, S., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0277 · Cited by 166 · see citing works
Pratley, R. E., Eldor, R., Raji, A., Golm, G. T., Huyck, S. B., Qiu, Y., Sunga, S., Johnson, J. R., Terra, S. G., Mancuso, J. P., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13194 · Cited by 162 · see citing works
Self-citationGlucagon-like peptide-1, glucose homeostasis and diabetes
Holst, J. J., Deacon, C. F., Vilsbøll, T., Krarup, T., & Madsbad, S. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.01.003 · Cited by 160 · see citing works
Mulherin, A. J., Oh, A., Kim, H., Grieco, A. J., Lauffer, L. M., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1485 · Cited by 158 · see citing works
Aschner, P. J., Katzeff, H. L., Guo, H., Sunga, S., Williams‐Herman, D., Kaufman, K. D., Goldstein, B. J., & for the Sitagliptin Study 049 Group (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01187.x · Cited by 157 · see citing works
Self-citationMohan, V., Yang, W., Son, H., Xu, L., Noble, L., Langdon, R. B., Amatruda, J. M., Stein, P. P., & Kaufman, K. D. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.10.009 · Cited by 157 · see citing works
Horton, E. S., Silberman, C., Davis, K. L., & Berria, R. (2010) · Diabetes Care · doi:10.2337/dc09-2062 · Cited by 156 · see citing works
Karasik, A., Aschner, P. J., Katzeff, H. L., Davies, M. J., & Stein, P. P. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x261069 · Cited by 155 · see citing works
Williams‐Herman, D., JOHNSON, J. R., Teng, R., Golm, G. T., Kaufman, K. D., Goldstein, B. J., & Amatruda, J. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01204.x · Cited by 154 · see citing works
Self-citationGPR119 agonists for the treatment of type 2 diabetes
Jones, R. M., Leonard, J. N., Buzard, D. J., & Lehmann, J. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903153878 · Cited by 154 · see citing works
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
Richter, B. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1707 · Cited by 150 · see citing works
Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Neumiller, J. J., Wood, L. D., & Campbell, R. K. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.5.463 · Cited by 149 · see citing works
Rosenstock, J., Chuck, L. H. S., González-Ortı́z, M., Merton, K., Craig, J., Capuano, G. A., & Qiu, R. (2016) · Diabetes Care · doi:10.2337/dc15-1736 · Cited by 143 · see citing works
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
Kishimoto, M. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s35682 · Cited by 138 · see citing works
Wu, D., Li, L., & Liu, C. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12174 · Cited by 131 · see citing works
Craddy, P., Palin, H. J., & Johnson, K. I. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0061-3 · Cited by 131 · see citing works
Dhillon, S. (2010) · Drugs · doi:10.2165/11203790-000000000-00000 · Cited by 128 · see citing works
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
Williams‐Herman, D., Round, E., Swern, A. S., Musser, B. J., Davies, M. J., Stein, P. P., Kaufman, K. D., & Amatruda, J. M. (2008) · BMC Endocrine Disorders · doi:10.1186/1472-6823-8-14 · Cited by 128 · see citing works
Self-citationWilliams‐Herman, D., Johnson, J. R., Teng, R., Luo, E., Davies, M. J., Kaufman, K. D., Goldstein, B. J., & Amatruda, J. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802705679 · Cited by 126 · see citing works
Self-citationSafety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Engel, S. S., Round, E., Golm, G. T., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0024-0 · Cited by 123 · see citing works
Self-citationVahed, T. A., Naimi‐Jamal, M. R., & Panahi, L. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.12.022 · Cited by 123 · see citing works
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121 · see citing works
Diabesity: therapeutic options
Colagiuri, S. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01182.x · Cited by 116 · see citing works
Kindel, T. L., Yoder, S. M., Seeley, R. J., D’Alessio, D. A., & Tso, P. (2009) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-009-0912-9 · Cited by 114 · see citing works
Therapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 113 · see citing works
DPP-4 inhibitors in the treatment of type 2 diabetes
Duez, H., Cariou, B., & Staels, B. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.028 · Cited by 113 · see citing works
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors
Pratley, R. E., & Gilbert, M. P. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.73 · Cited by 111 · see citing works
Godinho, R., Mega, C., Teixeira‐Lemos, E., Carvalho, E., Teixeira, F. J., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 109 · see citing works
Åhrén, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.003 · Cited by 108 · see citing works
Mendes, R., Sousa, N., Themudo-Barata, J. L., & Reis, V. M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16214163 · Cited by 106 · see citing works
Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-013-0169-1 · Cited by 106 · see citing works
Sifri, S. A., Basiounny, A., Echtay, A. S., Omari, M. A., Harman‐Boehm, I., KADDAHA, G., Tayeb, K., Mahfouz, A., Elq, A. H. A., Radican, L., et al. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02797.x · Cited by 104 · see citing works
Self-citationMyette‐Côté, É., Neudorf, H., Rafiei, H., Clarke, K., & Little, J. P. (2018) · The Journal of Physiology · doi:10.1113/jp275709 · Cited by 103 · see citing works
Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine
Mannino, G. C., Andreozzi, F., & Sesti, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3109 · Cited by 101 · see citing works
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis
Park, H., Park, C., Kim, Y. A., & Rascati, K. L. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r041 · Cited by 100 · see citing works
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 99 · see citing works
Gupta, V., & Kalra, S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.85583 · Cited by 99 · see citing works
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Engel, S. S., Golm, G. T., Shapiro, D., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-3 · Cited by 98 · see citing works
Self-citationAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
Fisman, E. Z., & Tenenbaum, A. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0294-0 · Cited by 96 · see citing works
Schwartz, S. L. (2010) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2010.10.003 · Cited by 95 · see citing works
Esposito, K., Cozzolino, D., Bellastella, G., Maiorino, M. I., Chiodini, P., Ceriello, A., & Giugliano, D. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01380.x · Cited by 95 · see citing works
Differing Effects of Metformin on Glycemic Control by Race-Ethnicity
Williams, L. K., Padhukasahasram, B., Ahmedani, B. K., Peterson, E. L., Wells, K. E., Burchard, E. G., & Lanfear, D. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1539 · Cited by 95 · see citing works
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
Åhrén, B. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802584126 · Cited by 94 · see citing works
Madsbad, S., Krarup, T., Deacon, C. F., & Holst, J. J. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328302f414 · Cited by 93 · see citing works
New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser
Cho, Y. M., & Kieffer, T. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1986-3 · Cited by 91 · see citing works
Reasner, C. A., Olansky, L., Seck, T. L., Williams‐Herman, D., Chen, M., Terranella, L., Johnson‐Levonas, A. O., Kaufman, K. D., & Goldstein, B. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01390.x · Cited by 89 · see citing works
Self-citationRegulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86 · see citing works
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
Flatt, P. R. (2008) · Frontiers in bioscience · doi:10.2741/2956 · Cited by 85 · see citing works
Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay
Niswender, K. D. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01175.x · Cited by 85 · see citing works
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Carolyn, F. D. (2007) · Frontiers in bioscience · doi:10.2741/2799 · Cited by 83 · see citing works
DPP4 Inhibitors: a new approach in diabetes treatment
Doupis, J., & Veves, A. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0076-1 · Cited by 83 · see citing works
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
Åhrén, B. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1944 · Cited by 83 · see citing works
The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
Filippatos, T. D., Athyros, V. G., & Elisaf, M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.907274 · Cited by 83 · see citing works
Cicero, A. F. G., Tartagni, E., & Ertek, S. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.31622 · Cited by 82 · see citing works
Johnston, R., Uthman, O. A., Cummins, E., Clar, C., Royle, P., Colquitt, J. L., Tan, B. K., Clegg, A. J., Shantikumar, S., Court, R. A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21020 · Cited by 81 · see citing works
Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
Richard, K. R., Shelburne, J. S., & Kirk, J. K. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.028 · Cited by 79 · see citing works
ß‐cell function and anti‐diabetic pharmacotherapy
Prato, S. D., Bianchi, C., & Marchetti, P. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.770 · Cited by 78 · see citing works
Hong, E. S., Khang, A. R., Yoon, J. W., Kang, S. M., Choi, S. H., Park, K. S., Jang, H. C., Shin, H., Walford, G. A., & Lim, S. K. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01600.x · Cited by 77 · see citing works
- Authors
- Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group
- Affiliations
- Thomas Jefferson University (US)
- Duke University (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Clinical and Quantitative Sciences, Merck Research Laboratories, Rahway, New Jersey
- ORCID
- Lunceford, Jared K.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-08-01
- Volume
- 30
- Issue
- 8
- Pages
- 1979-1987
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2113901579
- Cited by
- 509
- References
- 31
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 10 · 2021: 13 · 2020: 14 · 2019: 8 · 2018: 17 · 2017: 22 · 2016: 21 · 2015: 27 · 2014: 29 · 2013: 52 · 2012: 40
- FWCI
- 41.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- sitagliptin, metformin, combination therapy, type 2 diabetes, glycemic control, HbA1c, DPP-4 inhibitors, initial treatment, drug safety, adverse events, hypoglycemia, hyperglycemia, weight gain, antidiabetic drugs, open-label extension, fasting blood glucose
- MeSH terms
- Sitagliptin Phosphate, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Middle Aged, Placebos, Pyrazines, Triazoles, Single-Blind Method, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
